Results 1 to 10 of about 600,570 (203)
Network: Computation in Neural Systems, 2011 Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration. Eponymic diseases of the nervous system such as Alzheimer's, Parkinson's, and Huntington's diseases that were long characterized by mechanistic ignorance have yielded striking progress ...
D. Selkoe
semanticscholar +5 more sources
Nature Reviews Disease Primers, 2021 Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.
D. Knopman +7 more
semanticscholar +3 more sources
Donanemab in Early Alzheimer’s Disease
New England Journal of Medicine, 2021 BACKGROUND A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease.
Liana G. Apostolova +2 more
exaly +2 more sources
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Cell, 2017 Marco Colonna +2 more
exaly +2 more sources
Current Biology, 2018 The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later
Grøntvedt, G. +5 more
openaire +5 more sources
Lecanemab in Early Alzheimer's Disease.
New England Journal of Medicine, 2022 BACKGROUND The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease.
C. V. van Dyck +18 more
semanticscholar +1 more source
2023 Alzheimer's disease facts and figures
Alzheimer's & Dementia, 2023 This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society.
semanticscholar +1 more source
Scientific Reports, 2023 Although beta-amyloid (Aβ) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer’s disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation and
Xavier Morató +46 more
doaj +1 more source
Ameliorative effect of carveol on scopolamine induced memory impairment in rats [PDF]
Iranian Journal of Basic Medical Sciences, 2022 Objective(s): Carveol is a naturally occurring terpenoid with antispasmodic, carminative, astringent, indigestion, and dyspepsia properties, as well as anti-diabetic, anti-oxidant, anti-hyperlipidemia, and anti-inflammatory properties in the liver ...
Komal Latif +2 more
doaj +1 more source
Alzheimer’s Research & Therapy, 2022 Background FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid administrator errors.
Montserrat Alegret +24 more
doaj +1 more source